Biocon Limited — Updates, 06-03-2025: Press Release

Biocon Biologics Ltd has entered a strategic collaboration with Civica, Inc. to enhance access to Insulin Aspart in the United States. Under this agreement, Biocon Biologics will supply the drug substance for Insulin Aspart, which Civica will use to produce the final product at its Petersburg, Virginia facility. This partnership aims to meet the growing demand for affordable insulin, especially as around 38.4 million people in the U.S. are living with diabetes, many of whom struggle with affordability issues. The collaboration complements Biocon Biologics' ongoing efforts in the U.S. market, where its own Insulin Aspart product is currently awaiting FDA review. This initiative not only aligns with Biocon's mission to enhance patient access to vital medications but also positions the company positively for future growth in the biosimilars sector. Investors should monitor this collaboration for potential impacts on market share and revenue.